Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma

• Men and women 18 years of age and older
• Histologic proven advanced skin melanoma (Stage IV or stage IIIc inoperable) with BRAF V600 mutation
• Patient who will treated with combined kinase inhibitors (dabrafenib + trametinib).
• Patient able to stand a blood collection of 20 mL
• Ability to provide an informed written consent form
• Patient must be affiliated to a social security system
• Patient's legal capacity to consent to study participation and to understand and comply with the requirements of the study.

Exclusion Criteria:

• Patient with mucosal melanoma
• Patient with non-metastatic skin melanoma (All stages except stage IV and stage III C inoperable)
• Patient with another synchronous cancer, or within 3 years
• Patient with a contraindication to blood collection of 20 mL
• Patient deprived of liberty or under supervision
• Patient unable to receive kinase inhibitor therapy
• Patient treated with another combined kinase inhibitors than dabrafenib and trametinib
• Pregnant or breastfeeding women
• Patient (man or woman) of childbearing age who does not agree to use of contraceptive methods validated during the study